Tramarin, Anna
(2019)
Development of multimethodological strategies for monitoring biorecognition phenomena of pharmaceutically relevant targets, [Dissertation thesis], Alma Mater Studiorum Università di Bologna.
Dottorato di ricerca in
Scienze biotecnologiche e farmaceutiche, 31 Ciclo. DOI 10.6092/unibo/amsdottorato/8838.
Documenti full-text disponibili:
|
Documento PDF (English)
- Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (3MB)
|
Abstract
The comprehension of biorecognition phenomena is pivotal to clarify pathophysiological mechanisms and rationally develop new and more effective drugs. Amongst available analytical approaches to profile the binding partners, mass spectrometry (MS), circular dichroism (CD) and surface plasmon resonance (SPR) spectroscopies have been used to investigate two pharmaceutically relevant targets: human serum albumin (HSA) and human cholinesterases (ChEs).
Because of the role of HSA in several biological functions and its use in clinical practice as biological drug, it represents an important object of research. In this scenario, two studies were conducted. In the first, the binding capacity of pharmaceutical-grade HSA for infusion was studied by implementing a CD spectroscopy-based assay. A clear impairment of the binding capacity caused by the stabilizers sodium octanoate and N-acetyltryptophan, along with the impossibility of removing octanoate by common approaches, were highlighted. In the second study, SPR- and affinity chromatography-MS-based assays enabled an initial characterization of the interaction between glycated HSA and the receptor for advanced glycation end products (RAGE), providing further insights into the biorecognition phenomenon and laying the groundwork for subsequent studies on AGEs as more representative players in diabetes.
On the other hand, ChE enzymes are widely studied molecular targets in drug discovery for Alzheimer’s disease. Their inhibition still represents the main strategy to temporally counteract cognitive impairment and ameliorate patients’ quality of life. In this context, in solution functional assays were used for the identification of new potential inhibitors while a tailored SPR-based assay was developed to complement classic inhibition studies, helping the prioritization of favorite chemical scaffolds by providing affinity and kinetic parameters, including residence time. Overall, the tailored analytical strategies herein reported allowed to elucidate key biorecognition events, providing pivotal information which can help understanding pathological events as well as favoring the drug discovery process.
Abstract
The comprehension of biorecognition phenomena is pivotal to clarify pathophysiological mechanisms and rationally develop new and more effective drugs. Amongst available analytical approaches to profile the binding partners, mass spectrometry (MS), circular dichroism (CD) and surface plasmon resonance (SPR) spectroscopies have been used to investigate two pharmaceutically relevant targets: human serum albumin (HSA) and human cholinesterases (ChEs).
Because of the role of HSA in several biological functions and its use in clinical practice as biological drug, it represents an important object of research. In this scenario, two studies were conducted. In the first, the binding capacity of pharmaceutical-grade HSA for infusion was studied by implementing a CD spectroscopy-based assay. A clear impairment of the binding capacity caused by the stabilizers sodium octanoate and N-acetyltryptophan, along with the impossibility of removing octanoate by common approaches, were highlighted. In the second study, SPR- and affinity chromatography-MS-based assays enabled an initial characterization of the interaction between glycated HSA and the receptor for advanced glycation end products (RAGE), providing further insights into the biorecognition phenomenon and laying the groundwork for subsequent studies on AGEs as more representative players in diabetes.
On the other hand, ChE enzymes are widely studied molecular targets in drug discovery for Alzheimer’s disease. Their inhibition still represents the main strategy to temporally counteract cognitive impairment and ameliorate patients’ quality of life. In this context, in solution functional assays were used for the identification of new potential inhibitors while a tailored SPR-based assay was developed to complement classic inhibition studies, helping the prioritization of favorite chemical scaffolds by providing affinity and kinetic parameters, including residence time. Overall, the tailored analytical strategies herein reported allowed to elucidate key biorecognition events, providing pivotal information which can help understanding pathological events as well as favoring the drug discovery process.
Tipologia del documento
Tesi di dottorato
Autore
Tramarin, Anna
Supervisore
Dottorato di ricerca
Ciclo
31
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
surface plasmon resonance (SPR), circular dichroism (CD), affinity-mass spectrometry, kinetic analysis, residence time, acetylcholinesterase, RAGE, glycated albumin, human serum albumin, affinity constant, inhibitory potency, biorecognition phenomena, pharmaceutical analysis
URN:NBN
DOI
10.6092/unibo/amsdottorato/8838
Data di discussione
28 Marzo 2019
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Tramarin, Anna
Supervisore
Dottorato di ricerca
Ciclo
31
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
surface plasmon resonance (SPR), circular dichroism (CD), affinity-mass spectrometry, kinetic analysis, residence time, acetylcholinesterase, RAGE, glycated albumin, human serum albumin, affinity constant, inhibitory potency, biorecognition phenomena, pharmaceutical analysis
URN:NBN
DOI
10.6092/unibo/amsdottorato/8838
Data di discussione
28 Marzo 2019
URI
Statistica sui download
Gestione del documento: